Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent
Sponsors
Respirent Pharmaceuticals Co Ltd.
Conditions
Bioequivalence
Phase 1
A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
CompletedNCT04546256
Start: 2020-09-01End: 2020-12-31Updated: 2021-03-09
A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
CompletedNCT04564456
Start: 2020-09-22End: 2020-12-31Updated: 2021-01-20